SETTING: In KwaZulu-Natal, South Africa, a setting endemic for tuberculosis (TB) and the human immunodeficiency virus (HIV), prolonged hospitalisation for the treatment of the growing number of multidrug-resistant TB (MDR-TB) patients is neither possible nor effective. OBJECTIVE: To compare early treatment outcomes in patients with MDR-TB with and without HIV co-infection at four decentralised rural sites with a central urban referral hospital. DESIGN: This is an operational, prospective cohort study of patients between 1 July 2008 and 30 November 2009, where culture conversion, time to culture conversion, survival and predictors of these outcomes were analysed. RESULTS: Of 860 patients with MDR-TB, 419 were at the decentralised sites and 441 at the central hospital. Overall, 71% were HIV co-infected. In the 17-month study period, there was a higher proportion of culture conversion at the decentralised sites compared with the centralised hospital (54% vs. 24%, P < 0.001, OR 3.76, 95%CI 2.81-5.03). The median time to treatment initiation was significantly shorter at the decentralised sites compared with the centralised hospital (72 vs. 93 days, P < 0.001). There was no significant difference in survival following treatment initiation. CONCLUSION: In this study, early treatment outcomes suggest that decentralised care for MDR-TB patients is superior to that in a centralised setting.
SETTING: In KwaZulu-Natal, South Africa, a setting endemic for tuberculosis (TB) and the human immunodeficiency virus (HIV), prolonged hospitalisation for the treatment of the growing number of multidrug-resistant TB (MDR-TB) patients is neither possible nor effective. OBJECTIVE: To compare early treatment outcomes in patients with MDR-TB with and without HIV co-infection at four decentralised rural sites with a central urban referral hospital. DESIGN: This is an operational, prospective cohort study of patients between 1 July 2008 and 30 November 2009, where culture conversion, time to culture conversion, survival and predictors of these outcomes were analysed. RESULTS: Of 860 patients with MDR-TB, 419 were at the decentralised sites and 441 at the central hospital. Overall, 71% were HIV co-infected. In the 17-month study period, there was a higher proportion of culture conversion at the decentralised sites compared with the centralised hospital (54% vs. 24%, P < 0.001, OR 3.76, 95%CI 2.81-5.03). The median time to treatment initiation was significantly shorter at the decentralised sites compared with the centralised hospital (72 vs. 93 days, P < 0.001). There was no significant difference in survival following treatment initiation. CONCLUSION: In this study, early treatment outcomes suggest that decentralised care for MDR-TB patients is superior to that in a centralised setting.
Authors: K F Laserson; L E Thorpe; V Leimane; K Weyer; C D Mitnick; V Riekstina; E Zarovska; M L Rich; H S F Fraser; E Alarcón; J P Cegielski; M Grzemska; R Gupta; M Espinal Journal: Int J Tuberc Lung Dis Date: 2005-06 Impact factor: 2.373
Authors: Neel R Gandhi; N Sarita Shah; Jason R Andrews; Venanzio Vella; Anthony P Moll; Michelle Scott; Darren Weissman; Claudio Marra; Umesh G Lalloo; Gerald H Friedland Journal: Am J Respir Crit Care Med Date: 2009-10-15 Impact factor: 21.405
Authors: Carole Mitnick; Jaime Bayona; Eda Palacios; Sonya Shin; Jennifer Furin; Felix Alcántara; Epifanio Sánchez; Madeleny Sarria; Mercedes Becerra; Mary C Smith Fawzi; Saidi Kapiga; Donna Neuberg; James H Maguire; Jim Yong Kim; Paul Farmer Journal: N Engl J Med Date: 2003-01-09 Impact factor: 91.245
Authors: Jason E Farley; Malathi Ram; William Pan; Stacie Waldman; Gail H Cassell; Richard E Chaisson; Karin Weyer; Joey Lancaster; Martie Van der Walt Journal: PLoS One Date: 2011-07-22 Impact factor: 3.240
Authors: Kwonjune J Seung; David B Omatayo; Salmaan Keshavjee; Jennifer J Furin; Paul E Farmer; Hind Satti Journal: PLoS One Date: 2009-09-25 Impact factor: 3.240
Authors: Gabriel M Cohen; Paul K Drain; Farzad Noubary; Christie Cloete; Ingrid V Bassett Journal: J Acquir Immune Defic Syndr Date: 2014-11-01 Impact factor: 3.731
Authors: A S Dharmadhikari; M Mphahlele; K Venter; A Stoltz; R Mathebula; T Masotla; M van der Walt; M Pagano; P Jensen; E Nardell Journal: Int J Tuberc Lung Dis Date: 2014-09 Impact factor: 2.373
Authors: M Loveday; K Wallengren; J Brust; J Roberts; A Voce; B Margot; J Ngozo; I Master; G Cassell; N Padayatchi Journal: Int J Tuberc Lung Dis Date: 2015-02 Impact factor: 2.373
Authors: Jennifer A Gilbert; Elisa F Long; Ralph P Brooks; Gerald H Friedland; Anthony P Moll; Jeffrey P Townsend; Alison P Galvani; Sheela V Shenoi Journal: PLoS One Date: 2015-05-04 Impact factor: 3.240
Authors: Krisda H Chaiyachati; Marian Loveday; Stephen Lorenz; Neal Lesh; Lee-Megan Larkan; Sandro Cinti; Gerald H Friedland; Jessica E Haberer Journal: PLoS One Date: 2013-05-28 Impact factor: 3.240
Authors: Stellah G Mpagama; Scott K Heysell; Nora D Ndusilo; Happiness H Kumburu; Isack A Lekule; Riziki M Kisonga; Jean Gratz; Martin J Boeree; Eric R Houpt; Gibson S Kibiki Journal: PLoS One Date: 2013-05-13 Impact factor: 3.240